Valuation: Eagle Pharmaceuticals, Inc.

Market Cap 67.92M 59.66M 55.48M 50.91M 95.65M 6.54B 97.13M 659M 257M 3.22B 255M 249M 11.12B P/E 2021
-77x
P/E 2022 10.7x
Enterprise Value 78.11M 68.6M 63.8M 58.54M 110M 7.52B 112M 758M 296M 3.7B 293M 287M 12.79B EV / Sales 2021
3.44x
EV / Sales 2022 1.23x
Free-Float
74.04%
Yield 2021 *
-
Yield 2022 -
1 day+94.27%
1 week-67.21%
Current month-70.88%
1 month-67.48%
3 months-48.66%
6 months-72.13%
Current year-72.13%
1 week 0.08
Extreme 0.085
0.6
1 month 0.06
Extreme 0.0566
0.64
Current year 0
Extreme 0.0011
0.85
1 year 0
Extreme 0.0011
3.72
3 years 0
Extreme 0.0011
23.52
5 years 0
Extreme 0.0011
58.25
10 years 0
Extreme 0.0011
97.15
Manager TitleAgeSince
Chief Executive Officer 63 2023-11-26
Director of Finance/CFO 52 2024-11-10
Corporate Officer/Principal - 2022-07-17
Director TitleAgeSince
Director/Board Member 83 2007-02-28
Chairman 63 2016-06-28
Director/Board Member 65 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
2/28/24 Tax 2,119 0.0163%
2/27/24 Free

Chief Financial Officer

5,389 0.0415%
2/27/24 Free 16,104 0.1240%
Change 5-day change 1-year change 3-year change Capi.($)
+94.27%-67.21%-94.71%-98.94% 4.82M
+0.45%+2.80%+54.73%+21.89% 324B
-0.07%+2.09%+23.58%-11.37% 68.88B
+1.35%+5.29%+40.68%+91.38% 9.72B
+0.93%-1.38%+2.01%-3.34% 8.37B
+1.13%+1.51%-21.44%-1.35% 4.32B
+4.90%+5.79%-38.81%+23.85% 3.83B
-4.00%+0.71%-5.66%+13.37% 3.62B
-2.10%-3.83%+37.58%+52.58% 2.68B
-4.07%-2.45%-8.03%-16.98% 2.04B
Average +9.28%+1.11%-1.01%+7.11% 42.72B
Weighted average by Cap. +0.37%+2.17%+45.82%+17.33%

Financials

2021 2022
Net sales 172M 151M 140M 129M 242M 16.52B 245M 1.66B 650M 8.12B 644M 630M 28.08B 317M 278M 259M 237M 446M 30.49B 453M 3.07B 1.2B 14.99B 1.19B 1.16B 51.83B
Net income -8.63M -7.58M -7.05M -6.47M -12.15M -831M -12.34M -83.68M -32.69M -408M -32.39M -31.69M -1.41B 35.64M 31.3M 29.11M 26.71M 50.19M 3.43B 50.97M 346M 135M 1.69B 134M 131M 5.83B
Net Debt -67.84M -59.58M -55.41M -50.85M -95.54M -6.53B -97.01M -658M -257M -3.21B -255M -249M -11.11B 10.19M 8.95M 8.32M 7.64M 14.35M 981M 14.57M 98.81M 38.6M 482M 38.24M 37.42M 1.67B
Logo Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Employees
134
Date Price Change Volume
26-07-23 US$0.3700 -15.91% 984
26-07-21 US$0.4400 -26.05% 799
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EGRX Stock